Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxycycline + rifampicin + levofloxacin
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Shihezi University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**doxycycline + rifampicin + levofloxacin** is a triple-antibiotic combination therapy being investigated for the treatment of brucellosis, including uncomplicated and osteoarticular forms. The regimen combines three distinct mechanisms of action: **doxycycline** (a tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit; **rifampicin** (a rifamycin) inhibits DNA-dependent RNA polymerase, blocking transcription; and **levofloxacin** (a fluoroquinolone) inhibits DNA gyrase and topoisomerase IV, preventing DNA replication and repair. This combination is specifically designed to improve outcomes in osteoarticular brucellosis due to the superior bone and joint penetration of fluoroquinolones and to reduce the risk of antimicrobial resistance associated with rifampicin-based dual therapies. It is currently being evaluated in the multicenter BRUCE study led by The First Affiliated Hospital of Shihezi University.
- Other names
- Triple oral regimen (Doxycycline + Rifampicin + Levofloxacin)
02
Targets
Bacterial RibosomeDNA gyraseTopo IV (Bacterial Topoisomerase IV)rpoB (DNA-directed RNA polymerase subunit beta)
Beyond the preview
Go deeper on doxycycline + rifampicin + levofloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxycycline + rifampicin + levofloxacin.